Dots is a technology company.
Dots provides automation and insights for Discord and Slack, helping communities enhance member experiences through interactive onboarding and detailed analytics.
Dots has raised $13.0M across 2 funding rounds.
Dots has raised $13.0M in total across 2 funding rounds.
DOTS Technology Corp (also known as DOTS or Detection On The Spot) is a health tech company founded in 2013 that develops a diagnostics platform focused on point-of-care detection, primarily a consumer food allergen detector to test food for allergens before consumption.[1][4][5] Headquartered in Natick, Massachusetts, it has raised $30.9M in total funding through a Series B round, with investors including New Enterprise Associates, Alumni Ventures, and Felicis, and holds a granted patent for allergen detection technology.[1][4] The product serves consumers with food allergies, solving the problem of unsafe food intake by providing rapid, at-home testing to inform dietary decisions, positioning it in the growing healthcare diagnostics sector.[1][5]
While other entities share the "Dots" name—like Dots Tech for IT logistics/asset management and Dots Technologies for IT development—search results confirm DOTS as the primary match for a technology company with significant funding and patents in consumer health diagnostics.[1][2][3]
DOTS was founded in 2013 in Natick, Massachusetts, by a team aiming to revolutionize point-of-care diagnostics in healthcare.[1][4] The core idea emerged from addressing gaps in food allergen detection, leading to their first product: a consumer-facing device that detects allergens in food using advanced biotech methods, supported by a key patent filed in 2014 and granted in 2019 for "Allergen detection" involving molecular biology and DNA techniques.[1] Early traction included securing $30.9M in funding, with a $20.89M Series B round about 8 years ago, backed by prominent VCs like New Enterprise Associates, signaling pivotal validation in the health tech space.[1][5]
DOTS rides the wave of personalized health tech and point-of-care diagnostics, a trend accelerated by rising food allergy prevalence (affecting ~32M Americans) and demand for consumer empowerment post-pandemic.[1][5] Timing aligns with biotech advances in portable DNA testing, making at-home allergen detection feasible amid market forces like regulatory pushes for food safety and growth in the $50B+ diagnostics industry. By enabling proactive consumer decisions, DOTS influences the ecosystem, potentially inspiring similar devices for other allergens or industrial uses, while bridging health tech with everyday consumer products.[1][4][5]
DOTS is poised to capitalize on expanding at-home health diagnostics, potentially launching commercial products or new applications beyond food allergens, driven by its patented tech and investor support.[1][5] Trends like AI-enhanced biotech and global allergy awareness will shape its path, with influence evolving toward broader point-of-care solutions if it overcomes scaling hurdles from its last funding 8 years ago. This positions DOTS as a key player in making diagnostics accessible, tying back to its mission of safer food decisions through innovative detection.[1][4]
Dots has raised $13.0M in total across 2 funding rounds.
Dots's investors include Big Sky Health, Coinbase Ventures, Connect Ventures, Corazon Capital, Creative Juice, ENIAC Ventures, Jenny Fielding, Scott Hartley, Exponent Founders Capital, Firstminute Capital, Freestyle Capital, Future Africa.
Dots has raised $13.0M across 2 funding rounds. Most recently, it raised $3.0M Seed in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $3.0M Seed | Big Sky Health, Coinbase Ventures, Connect Ventures, Corazon Capital, Creative Juice, ENIAC Ventures, Jenny Fielding, Scott Hartley, Exponent Founders Capital, Firstminute Capital, Freestyle Capital, Future Africa, General Catalyst, Kamay Ventures, Luno Expeditions, Maven Ventures, Montage Ventures, Norrsken VC, OurCrowd, Precursor Ventures, QED Investors, Quona Capital, Stellar Capital, Tekton Ventures, The Community Fund, Vera Equity, Andre Mohamed, Brad Garlinghouse, Charles Delingpole, David de Picciotto, Eric Hahn, Gabriel Weinberg, Iqram Magdon-Ismail, Jason Gardner, Jason Goldberg, Richard Chen, Tom Blomfield, Trevor Noah | |
| Dec 1, 2014 | $10.0M Series A | Betaworks Ventures, Brainchild, LightShed Ventures, Pareto Holdings, Red Sea Ventures, The General Partnership, Wellington Management, Dennis Crowley, Scott Belsky |